Provided are compounds of Formula I; and pharmaceutically acceptable salts and solvates thereof. The compounds of Formula I described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.

Provided are compounds of Formula I; and pharmaceutically acceptable salts and solvates thereof. The compounds of Formula I described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.

Disclosed herein are water-soluble UV absorbing compounds of Formula I with two quaternary ammonium centers, wherein;

##STR00001##

R is selected from saturated or unsaturated alkyl groups with C.sub.12 to C.sub.22 carbon atoms and R.sub.1 is selected from H or methoxy group. The invention further discloses the synthesis of highly substantive water-soluble UV absorbers containing two quaternary ammonium centers, cinnamidopropyl (2-hydroxypropyl alkyl dimethyl ammonium chloride) dimonium chlorides of Formula I and the compositions containing the same in personal care products.

The invention relates to a kind of medicinal salts of polyamine derivatives, preparation method and use thereof in preparation of a drug for treating sepsis. These novel compounds have good antagonistic action on a plurality of pathogen-associated molecular patterns that induce sepsis, such as bacterial lipopolysaccharide (endotoxin), bacterial genomic DNA, peptidoglycan, lipoteichoic acid, virus RNA, and zymosan, and can be used for preparation of a drug for treating sepsis.

Provided herein is a two-component photosensitizer, which demonstrated robust and selective killing effects for transfected HEK cells and affibody targeted A431 cancer cells when exposed to near infrared light excitation. Free MG2I is a pure and stable fluorogen; it is easy to synthesize and modify, and has no toxicity to cells. Unlike conventional photosensitizers, the dye and FAP itself has no photosensitizing effect until they are bound. Also unlike other activation methods, the activation step is achieved by adding the fluorogen, not the presence of the targeted molecule, requiring an active activation instead of a passive activation. This method offers the ability to locally switch-on and selective generation of singlet oxygen at the target site and can be used for a wide variety of molecular targets.

Provided herein is a two-component photosensitizer, which demonstrated robust and selective killing effects for transfected HEK cells and affibody targeted A431 cancer cells when exposed to near infrared light excitation. Free MG2I is a pure and stable fluorogen; it is easy to synthesize and modify, and has no toxicity to cells. Unlike conventional photosensitizers, the dye and FAP itself has no photosensitizing effect until they are bound. Also unlike other activation methods, the activation step is achieved by adding the fluorogen, not the presence of the targeted molecule, requiring an active activation instead of a passive activation. This method offers the ability to locally switch-on and selective generation of singlet oxygen at the target site and can be used for a wide variety of molecular targets.

Provided are compounds of Formula I: ##STR00001##
and pharmaceutically acceptable salts and solvates thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are as described herein. The compounds of Formula I are agonists of the kappa opioid receptor and relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.

Provided are compounds of Formula I: ##STR00001##
and pharmaceutically acceptable salts and solvates thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are as described herein. The compounds of Formula I are agonists of the kappa opioid receptor and relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.

The present invention provides novel N-aralkylcarbonyldiamine compounds having a structure as set forth in Structure I. The structures are not quaternized. When these novel unquaternized compounds are used in personal care compositions, particularly personal care skin compositions, they are more stable and provide unexpected cosmetic advantages (e.g., against wrinkles, aging skin, etc.) when delivered from the personal care skin compositions.

The present invention provides novel N-aralkylcarbonyldiamine compounds having a structure as set forth in Structure I. The structures are not quaternized. When these novel unquaternized compounds are used in personal care compositions, particularly personal care skin compositions, they are more stable and provide unexpected cosmetic advantages (e.g., against wrinkles, aging skin, etc.) when delivered from the personal care skin compositions.